Amenorrhea natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 34: Line 34:
*Among patients of [[androgen insensitivity syndrome]] there is an increased risk of [[testicular cancer]], and surveillance is needed appropriate intervals.
*Among patients of [[androgen insensitivity syndrome]] there is an increased risk of [[testicular cancer]], and surveillance is needed appropriate intervals.
*[[Prognosis]] of [[Polycystic ovary syndrome|polycystic ovary syndrome (PCOS)]] is generally good. Long term dietary management and [[exercise]] along with [[metformin]] therapy decreases the [[cardiovascular]] and [[pregnancy]] complications in the future.<ref name="pmid18007129">{{cite journal |vauthors=Hart R |title=Polycystic ovarian syndrome--prognosis and treatment outcomes |journal=Curr. Opin. Obstet. Gynecol. |volume=19 |issue=6 |pages=529–35 |year=2007 |pmid=18007129 |doi=10.1097/GCO.0b013e3282f10e22 |url=}}</ref>
*[[Prognosis]] of [[Polycystic ovary syndrome|polycystic ovary syndrome (PCOS)]] is generally good. Long term dietary management and [[exercise]] along with [[metformin]] therapy decreases the [[cardiovascular]] and [[pregnancy]] complications in the future.<ref name="pmid18007129">{{cite journal |vauthors=Hart R |title=Polycystic ovarian syndrome--prognosis and treatment outcomes |journal=Curr. Opin. Obstet. Gynecol. |volume=19 |issue=6 |pages=529–35 |year=2007 |pmid=18007129 |doi=10.1097/GCO.0b013e3282f10e22 |url=}}</ref>
*[[Prognosis]] is excellent for hyperprolactinemia. Depending on the size of the [[tumor]] and the extent of [[tumor]] resection, the rate of recurrence may range from 20% to 50%. The majority of recurrent prolactinomas develop within the first 5 years.<ref>http://www.niddk.nih.gov/health-information/health-topics/endocrine/prolactinoma/Pages/fact-sheet.aspx</ref>
*[[Prognosis]] is excellent for hyperprolactinemia due to microprolactinoma. Depending on the size of the [[tumor]] and the extent of [[tumor]] resection, the rate of recurrence may range from 20% to 50%. The majority of recurrent prolactinomas develop within the first 5 years.<ref>http://www.niddk.nih.gov/health-information/health-topics/endocrine/prolactinoma/Pages/fact-sheet.aspx</ref>
 
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Latest revision as of 13:37, 3 November 2017

Amenorrhea Microchapters

Home

Patient Information

Primary amenorrhea
Secondary amenorrhea

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Amenorrhea from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Amenorrhea natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Amenorrhea natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Amenorrhea natural history, complications and prognosis

CDC on Amenorrhea natural history, complications and prognosis

Amenorrhea natural history, complications and prognosis in the news

Blogs on Amenorrhea natural history, complications and prognosis

Directions to Hospitals Treating Amenorrhea

Risk calculators and risk factors for Amenorrhea natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

If left untreated, patients with amenorrhea may progress to develop infertility and osteoporosis. Common complications of amenorrhea are based on underlying disorder that induce amenorrhea. Prognosis is generally excellent and the mortality rate of patients with amenorrhea is approximately less than 1%, generally in patients with brain lesions.

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

References

  1. Palomba S, Santagni S, Falbo A, La Sala GB (2015). "Complications and challenges associated with polycystic ovary syndrome: current perspectives". Int J Womens Health. 7: 745–63. doi:10.2147/IJWH.S70314. PMC 4527566. PMID 26261426.
  2. 2.0 2.1 Meczekalski B, Katulski K, Czyzyk A, Podfigurna-Stopa A, Maciejewska-Jeske M (2014) Functional hypothalamic amenorrhea and its influence on women's health. J Endocrinol Invest 37 (11):1049-56. DOI:10.1007/s40618-014-0169-3 PMID: 25201001
  3. Vegetti W, Marozzi A, Manfredini E, Testa G, Alagna F, Nicolosi A, Caliari I, Taborelli M, Tibiletti MG, Dalprà L, Crosignani PG (2000). "Premature ovarian failure". Mol. Cell. Endocrinol. 161 (1–2): 53–7. PMID 10773392.
  4. Mattei AM, Severini V, Crosignani PG (1991). "Natural history of hyperprolactinemia". Ann. N. Y. Acad. Sci. 626: 130–6. PMID 2058949.
  5. Sanfilippo JS (1999). "Implications of not treating hyperprolactinemia". J Reprod Med. 44 (12 Suppl): 1111–5. PMID 10649820.
  6. "Premature ovarian failure - Symptoms and causes - Mayo Clinic".
  7. Nelson LM (2009). "Clinical practice. Primary ovarian insufficiency". N Engl J Med. 360 (6): 606–14. doi:10.1056/NEJMcp0808697. PMC 2762081. PMID 19196677.
  8. Hart R (2007). "Polycystic ovarian syndrome--prognosis and treatment outcomes". Curr. Opin. Obstet. Gynecol. 19 (6): 529–35. doi:10.1097/GCO.0b013e3282f10e22. PMID 18007129.
  9. http://www.niddk.nih.gov/health-information/health-topics/endocrine/prolactinoma/Pages/fact-sheet.aspx

Template:WH Template:WS